Exogenous p53 Upregulated Modulator of Apoptosis (PUMA) Decreases Growth of Lung Cancer A549 Cells

Chun-Ju Liu1,2&, Xia-Li Zhang1&, Da-Ya Luo1, Wei-Feng Zhu1, Hui-Fang Wan1, Jun-Ping Yang2, Xiao-Jun Yang2, Fu-Sheng Wan1*

Abstract

Purpose: To investigate the influence of exogenous p53 upregulated modulator of apoptosis (PUMA) expression on cell proliferation and apoptosis in human non-small cell lung cancer A549 cells and transplanted tumor cell growth in nude mice. Materials and Methods: A549 cells were divided into the following groups: control, non-carrier (NC), PUMA (transfected with pCEP4-HA) 2-PUMA plasmid), DDP (10μg/mL cisplatin treatment) and PUMA+DDP (transfected with pCEP4-HA)2-PUMA plasmid and 10μg/mL cisplatin treatment). The MTT method was used to detect the cell survival rate. Cell apoptosis rates were measured by flow cytometry, and PUMA, Bax and Bcl-2 protein expression levels were measured by Western blotting. Results: Compared to the control group, the PUMA, DDP and PUMA+DDP groups all had significantly decreased A549 cell proliferation (p<0.01), with the largest reduction in the PUMA+DDP group. Conversely, the apoptosis rates of the three groups were significantly increased (P<0.01), and the PUMA and DDP treatments were synergistic. Moreover, Bax protein levels significantly increased (p<0.01), while Bcl-2 protein levels significantly decreased (p<0.01). Finally, both the volume and the weights of transplanted tumors were significantly reduced (p<0.01), and the inhibition ratio of the PUMA+DDP group was significantly higher than in the single DDP or PUMA groups. Conclusions: Exogenous PUMA effectively inhibited lung cancer A549 cell proliferation and transplanted tumor growth by increasing Bax protein levels and reducing Bcl-2 protein levels.

Keywords: p53 upregulated modulator of apoptosis - non-small cell lung cancer - apoptosis - tumor transplant

Asian J Cancer Prev, 16 (2), 741-746

Introduction

One of the most common malignant tumors that threatens human health, lung cancer has the highest mortality worldwide. In China, lung cancer ranks second, or even first in some cities, as the cause for malignant tumor death (Zaffaroni et al., 2007; Watanabe et al., 2009; Rouibaa et al., 2013). Non-small cell lung cancer (NSCLC) accounts for 80-85% of lung cancer. The standard treatment approach for NSCLC is surgical treatment coupled with chemotherapy and radiotherapy, which has a five-year survival rate of less than 40% (Zaffaroni et al., 2007; Watanabe et al., 2009).

Tumors are caused by abnormal cell proliferation, differentiation and apoptosis due to activation of certain proto-oncogenes, inactivation of tumor suppressors and changes to apoptosis-related genes (Kuo et al., 2012; Berna et al., 2012). Thus, many studies search for ideal target genes for gene therapy (Gao et al., 2013). It has been reported that overexpression of the anti-apoptotic gene Bcl-2 and decreased expression of the pro-apoptotic gene Bax could inhibit cellular apoptosis, promoting the important mechanisms of tumor development - cell survival and proliferation (Meng et al., 2010; Perez et al., 2013). Hence, it is important to study Bcl-2 and Bax gene expression in pre-cancerous pathological changes for early lung cancer diagnoses.

p53 upregulated modulator of apoptosis (PUMA) is a BH3-only protein family member that has the strongest pro-apoptotic effects found in recent years (Yu, 2009). As the main apoptosis-promoting protein upstream of Bax/Bak, PUMA is able to obstruct the function of all Bcl-2 anti-apoptotic proteins. When stimulated by various pathological factors, PUMA plays an essential role in activating apoptosis through both p53-dependent and independent pathways (Jeffers et al., 2003; Wang et al., 2007; Avila et al., 2009; Niizuma et al., 2009; Yu, 2009). Regardless of the method of pathway activation, PUMA interacts with the anti-apoptotic proteins Bcl-2, Bcl-xL, Bcl-W and Mcl-1 via its BH3 structural domain to induce cell apoptosis (Han, 2001; Yee and Vousden, 2008). Many studies have confirmed that PUMA is a necessary mediator of cell apoptosis and have elaborated on the pro-apoptotic mechanisms, providing new targets for anti-tumor therapies. The objective of this study was to investigate the influence of exogenous PUMA on cell proliferation,
growth and apoptosis in NSCLC A549 cells. To do this, we transfected the wild-type PUMA gene into human NSCLC A549 cells and analyzed PUMA, Bcl-2 and Bax protein expression. Additionally, the therapeutic effects of exogenous PUMA on NSCLC A549 cells transplanted into nude mice were studied by analyzing PUMA, Bcl-2 and Bax protein expression. Our results have important implications for tumor gene therapy and provide a new experimental basis for clinical application.

Materials and Methods

Reagents and antibodies

RPMI1640, DMEM (Dulbecco’s Modified Eagle’s Medium) culture media and fetal bovine serum were purchased from Gibco; Parenzyme, SDS, TEMED, β-actin monoclonal antibody, HA monoclonal antibody (Cat. TA-04), Bcl-2 monoclonal antibody (sc-783) and Bax monoclonal antibody (sc-526) were purchased from Santa Cruz Biotechnology; PUMA polyclonal antibody (Cat. #51201-1-AP) was purchased from USA Proteintech; IgG (ZDR-5307) and IgG (ZDR-5306) were purchased from Beijing ZSGB-Bio Company; DDP cisplatin was purchased from Shandong Qilu Pharmaceutical Co., Ltd.

Cells and animals

Human NSCLC A549 cells were purchased from the cell bank of the Typical Culture Preservation Committee, Chinese Academy of Sciences, 4-week old BALB/C nude mice weighing 20g with a male-to-female ratio of 1:1 (SPF level, Certificate No.: HNASLKJ20121369) were purchased from Hunan Slack King Laboratory Animal Co. Ltd. They were maintained in IVC caging with constant temperature and humidity.

Experiment grouping and drug treatments

The NSCLC A549 cells were cultured in RPMI1640 complete culture solution containing 10% FBS in a 37°C, 5% CO2 incubator. The experiment included five groups: (1) control (only transfection reagents added); (2) NC (transfected with pCEP4-(HA)-2-C1 plasmid); (3) PUMA (transfected with pCEP4-(HA)-2-PUMA plasmid); (4) DDP (treated with 10μg/ml cisplatin); and (5) PUMA+DDP (transfected with pCEP4-(HA)-2-PUMA plasmid and treated with 10μg/ml cisplatin).

Detection of cell survival rate by MTT

Logarithmic phase cells were collected and seeded in a 96-well plate at a density of 3000-8000/well. Four parallel wells were set up, and marginal wells were filled with aseptic PBS. The cells were then cultivated in a 37°C, 5% CO2 incubator for 48h, followed by another 4h after 20μL of 5mg/mL MTT was added to each well. Then, 150µL DMSO was added to each well after the previous liquid was absorbed. The 96-well plate was mixed for 10min on a horizontal oscillating table to thoroughly dissolve the crystals. Afterwards, the OD value of each well was measured by an enzyme-linked immunosorbent assay (ELISA) reader at 490nm. The data was recorded to determine the inhibition ratio as follows: Inhibition ratio (%)=(1-OD value of the experimental group/OD value of the control group)×100.

Transfection

Polyfectine in vitro transfection reagent was used to transfect the pCEP4-(HA) 2-PUMA recombinant plasmid and non-carrier plasmid pCEP4-(HA)-2-C1 into A549 cells. The logarithmic phase A549 cells were transferred to a 6-well plate. When the cells reached a density of 70-90% the next day, transient transfection was conducted. Before the transfection, the old culture media was removed and replaced with 900mL fresh complete media for each well. Cultivation lasted for 30-60min. Each well received 100μL Polyfectine and was placed in a 37°C, 5% CO2 incubator for 6h. After incubation, wells were washed with serum free media 3 times, and then complete media was added to the cells for another 24h for subsequent experiments.

Observation of cellular apoptotic morphology by Hoechst 33342 staining

Logarithmic phase cells were collected and seeded into a 12-well plate. When the cells reached a density of 70-90% the next day, the treatments were added. For each group, three parallel wells were set up. The 12-well plate was placed in a 37°C, 5% CO2 incubator for 48h. After discarding the treatment solutions, the plate was rinsed twice with PBS. Then, cellular apoptotic morphology was observed and photographed by fluorescence microscope. 10 random high magnifications were selected to calculate the cellular apoptosis rate, where apoptosis rate (%)=apoptotic cells/total cells×100.

Detection of tumor cellular apoptosis rate by flow cytometry

After the 48h treatment, 1-5×10^6 cells were collected. 500μL binding buffer suspension cells were added and blended with 5μL annexin V-FITC and 5μL propidium iodide, respectively, in order to enable a 5-15 min reaction at room temperature in the dark. Cellular apoptosis was detected using a FACSCalibur flow cytometry machine (USA, Becton Dickinson).

Measurement of PUMA, Bax and Bcl-2 protein expression by Western blot

After collection and denaturation, 30μg of protein were electrophoresed through an SDS-PAGE gel. The proteins were transferred to PVDF film and incubated with PUMA, Bax and Bcl-2 antibodies (1:200). After overnight incubation at 4°C, PVDF was then incubated with hors eradish peroxidase-conjugated secondary antibody (1:2000) for 1.5 h. Finally, ECL immunodetection was performed in a dark room. Image-Pro Plus 6.0 gel image analyzing software was used to scan the grayscale value of protein bands. Semi-quantitative analyses were performed using the internal control GAPDH as the control bands.

Tumor cell transplantation in nude mice

40, 4-week-old nude mice were subcutaneously...
injected with A549 cells on their left and right backs. When the tumor tissue blocks reached 2-3mm in diameter, mice were divided into 5 groups: control group (injected with 0.1mL physiological saline into and around the tumor), negative control group (injected with 0.1mL mixture of pCEP4-(HA)2-C1 plasmid (100µg) and liposome into and around the tumor), positive control group (injected with 0.1mL DDP (5mg/kg) into the abdominal cavity), PUMA treatment group (injected with 0.1mL mixture of pCEP4-(HA)2-C1 plasmid (100µg) and liposome into and around the tumor) and combined treatment group (injected with 0.1mL DDP (5mg/kg) into the abdominal cavity and 0.1mL mixture of pCEP4-(HA)2-C1 plasmid (100µg) and liposome into and around the tumor).

**Immunohistochemistry analyses**

The mice were euthanized, photographed and weighed. The tumor block was taken out and washed with PBS to remove any blood. Then, the tumor was photographed, weighed and immediately fixed in 4% paraformaldehyde. Immunohistochemistry was used to measure PUMA, Bax and Bcl-2 protein expression levels for each group. At high magnification (40×) using an Olympus BX-41 binocular optical microscope, two discontinuous immunohistochemistry slices were measured for each group, with each slice observed in five visual fields. Then, the HMIAS-2000 imaging analysis system was used to photograph the fields and to automatically calculate the integral optical density of PUMA, Bax and Bcl-2 protein expression.

**Statistical analyses**

SPSS (version 17.0) was used to analyze the experimental data, which are presented as the means±SD. One-way ANOVA or non-paired t-test was performed to analyze intra-group parameters, and the q-test was used to conduct pairwise comparisons among the groups. The difference is significant if \( p < 0.05 \).

**Results**

**Influence of exogenous PUMA on human NSCLC A549 cell proliferation**

Results are shown in Figure 1. Figure 1A shows that PUMA gene transfection inhibited cell growth at 24 h. The inhibitory effect was the greatest at 48h, while it significantly decreased at 72 h. Conversely, the inhibition rate was not significantly different for the control and NC groups (\( p > 0.05 \)). Compared to the control group, the PUMA, DDP and PUMA+DDP groups had significant inhibition of A549 cell proliferation (\( p < 0.01 \)) (Figure 1B). The greatest inhibition was in the PUMA+DDP group, indicating that there was a synergistic reaction between PUMA and DDP treatments. These results show that the combined application of PUMA and DDP greatly inhibited A549 cell proliferation.

**Influence of exogenous PUMA on human NSCLC A549 cell apoptosis**

Results are shown in Figures 2 and 3. Figure 2 shows that the A549 cellular apoptosis rate in the PUMA and PUMA+DDP groups was significantly increased (\( p < 0.01 \)) compared to the control group, revealing a synergistic reaction between PUMA and DDP. The apoptosis rate of the NC group was not different from the control group (\( p > 0.05 \)). These results indicate that PUMA gene transfection promoted A549 cell apoptosis, and that even more apoptosis resulted from combined PUMA and DDP treatment.

Figure 3 shows A549 cell apoptosis measured by Hoechst 33342 fluorescent staining after 48 h of PUMA gene transfection and DDP treatment. The images show that nuclei of the control group are light blue and

---

**Figure 1. The Proliferation Inhibition Rates of each Treatment Group of A549 Cells.** *\( p < 0.01 \) vs. 24 h group; **\( p < 0.01 \) vs. Control group

**Figure 2. Flow cytometry analyses of apoptosis rates of each treatment group of A549 cells.** A) Control group; B. NC group; C. PUMA group; D. DDP group; E. PUMA + DDP group; F. The statistical analysis of the apoptosis rate of A549 cells. *\( p < 0.05 \), **\( p < 0.01 \) vs control or NC; #\( p < 0.05 \) vs PUMA; \( ^* p < 0.05 \) vs DDP

**Figure 3. Protein Expression of PUMA, Bax and Bcl-2 for Each Treatment Group of A549 Cells.** lane a=Control group, lane b=NC group, lane c=PUMA group, lane d=DDP group, lane e=PUMA+DDP group, **\( p < 0.01 \) vs. control or NC
circular, while nuclei of apoptotic cells are deep blue with apoptotic bodies. Compared to the control and NC groups, more apoptotic cells were seen in the PUMA group (p<0.05). Additionally, the amount of apoptotic cells in the PUMA+DDP group was significantly higher than that of the control and NC groups (p<0.01). These results demonstrated that high expression of the PUMA gene promoted A549 cell apoptosis and apoptosis was exacerbated when PUMA and DDP treatments were combined.

Influence of exogenous PUMA on PUMA, Bax and Bcl-2 protein expression in human NSCLC A549 cells

The Western blot results show HA protein expression in the NC, PUMA and PUMA+DDP groups, indicating successful transfection (Figure 4A, B). Compared to the control and NC groups, the PUMA, DDP and PUMA+DDP groups had significantly higher expression of the apoptosis-promoting protein Bax (Figure 4D) (p<0.05) and significantly lower expression of the anti-apoptosis protein Bcl-2 (Figure 4C) (p<0.05). The Bax/Bcl-2 ratios were increased (Figure 4D).

Influence of exogenous PUMA on growth of human NSCLC A549 tumor cells transplanted in nude mice

Figure 5 shows that the average tumor inhibition rates of the PUMA, DDP and PUMA+DDP groups were 43.25±1.86%, 55.56±3.88% and 77.59±1.24%, respectively. These inhibition rates are significantly higher than that of the control and NC groups (p<0.01). Additionally, the average tumor weight and volume for each treatment group was significantly lower than the control and NC groups (p<0.01). Furthermore, the PUMA+DDP group had a much higher inhibition rate than the PUMA and DDP groups. These results indicate that there was a synergistic relationship between PUMA and DDP. Their combination more effectively inhibited growth of tumor cells transplanted in nude mice.
Influence of exogenous PUMA on PUMA, Bax and Bcl-2 protein expression in tumor cells transplanted in nude mice

Immunohistochemical analyses of PUMA, Bax and Bcl-2 proteins (Figures 6-8) shows that PUMA, Bax and Bcl-2 proteins in cells are cytolymph positive. Compared to the control and NC groups, the PUMA, DDP and PUMA+DDP groups had significantly higher positive cytolymph staining of PUMA and Bax proteins (p<0.01), with the most positive staining in the PUMA+DDP group. The positive cytolymph staining of Bcl-2 protein, however, was significantly decreased in the PUMA, DDP and PUMA+DDP groups (p<0.01), with the least positive staining in the PUMA+DDP group. These results show that the effects in the PUMA+DDP group were significantly higher than in the PUMA and DDP groups.

Discussion

A respiratory system tumor with high mortality and recurrence rates, lung cancer is the most common malignant tumor and cause of death globally (Lovet et al., 2003). Chemotherapy kills tumor cells by activating apoptosis, while apoptotic pathway defects are associated with tumor resistance to chemotherapy. Because of the side effects and tumor cell insensitivities, chemotherapy drugs in clinical applications are greatly restricted.

Using three different strategies, Yu (2001), Nakano (2001) and Han (2001) discovered the PUMA gene in 2001. PUMA was so named because it can be rapidly induced by p53 and has powerful apoptosis-promoting effects. The PUMA gene is located at 19q31, with a 1.9kb total length of cDNA. There are five exons (1a/1b, 2, 3, 4) and three introns, which form four different spliceosomes after transcription (PUMAα, PUMAβ, PUMAγ and PUMAσ). PUMAγ and PUMAσ lack the BH3 structural domain and, consequently, do not have pro-apoptotic functions. The most widely studied, PUMAα encodes a protein with 193 amino acid residues and has a BH3 structural domain. Additionally, there are no homogenous regions when compared with other known proteins (Yu, 2009).

The introduction of apoptotic genes could increase sensitivity to chemotherapy drugs. In fact, Wang et al., treated human esophageal cancer cells by combining a recombinant adenovirus (Ad-PUMA, Ad-p53) carrying PUMA and p53 with the anti-cancer drugs cisplatin, paclitaxel and 5-fluorouracil (Wang et al., 2006). This study showed that PUMA greatly improved the sensitivity of esophageal cancer cells to chemotherapy drugs by inducing cellular apoptosis. While investigating PUMA-transfected drug-resistant choriocarcinoma cells jeg-3/vp16, Chen et al., (2007) demonstrated that Ad-PUMA significantly increased choriocarcinoma sensitivity to chemotherapy drugs, and that combined application of PUMA and chemotherapy drugs promoted choriocarcinoma cell apoptosis. Furthermore, Roberts et al., (2011) reported that upregulation of PUMA expression is an effective treatment for mammary cancer.

In our previous study, Taurine caused human colon carcinoma cell apoptosis by upregulating PUMA gene expression independent of the p53 gene (Zhang et al., 2014). In this study, the pCEP4-(HA)2-PUMA recombinant plasmid was successfully transfected into NSCLC A549 cells, resulting in high expression of the wild type PUMA gene. Moreover, we found that exogenous PUMA transfection could inhibit proliferation in both human NSCLC A549 cells (Figure 1) and tumor cells transplanted in nude mice (Figure 5), and promoted apoptosis (Figures 2, 3). Interestingly, combined application of PUMA and DDP had the synergistic effects of inhibiting transplanted tumor growth in nude mice and increasing cancer cell sensitivity to chemotherapy drugs. In this experiment, the PUMA+DDP group demonstrated a significantly higher apoptosis rate than the PUMA and DDP groups, showing that overexpression of the PUMA gene in A549 cells improved the sensitivity of tumor cells to DDP and enhanced the anti-tumor characteristics of DDP. These data suggest that it is possible to achieve therapeutic effects when using a smaller dosage of DDP to alleviate side effects. The results of this study indicate that exogenous PUMA gene transfection has great potential applications in lung cancer treatment.

PUMA is a BH3-only protein family member that has the strongest apoptosis-promoting effects found in recent years and plays a significant role in apoptotic pathways (Wan et al., 2013). In vitro studies have shown that PUMA affects tumor cell proliferation and induces cellular apoptosis independent of p53, which led to high hopes of using PUMA for tumor therapy (Sun et al., 2007; Wang et al., 2012). Yu et al., (2006) found that PUMA induced lung cancer cell apoptosis and inhibited cell proliferation via caspase activation and cytochrome c release in non-chemoradiotherapy sensitive lung cancers, providing evidence that PUMA can increase sensitivity to radiotherapy and chemotherapy drugs.

In our experiments, we used the Polyfectine in vitro DNA transfection reagent to mediate eukaryotic expression vector transfection of human NSCLC A549 cells. Western blot analyses showed that after PUMA gene transfection the expression of the apoptosis-
Chun-Ju Liu et al

promoting protein Bax significantly increased (p<0.05) and the expression of the anti-apoptosis protein Bcl-2 decreased. In the Bcl-2 family, the ratio of pro-apoptotic to anti-apoptotic proteins is a key factor in determining the occurrence and level of apoptosis. The proportion of pro-apoptotic proteins in cells also determines the cellular response to death signals and cell destiny. It has been reported that decreased Bax protein expression is related to the sensitivity of tumor cells to chemotherapy and the length of patient survival times (Singh et al., 2006). In our paper, the immunohistochemical results of human NSCLC A549 tumor cell transplantation in nude mice are consistent with Western blot results, further verifying that PUMA gene transfection promotes lung cancer cell apoptosis.

In conclusion, PUMA is an important mediator of cell apoptosis and is a novel and promising target for anti-tumor therapy. The biggest challenge to using PUMA in the clinic will be increasing the specificity of PUMA in anti-tumor therapy. Future research directions should involve increasing PUMA protein expression in tumor cells based on the carrier’s targeting specificity and inducing tumor cell apoptosis without affecting normal cells.

References


Yu J. PUMA, a potent killer with or without p53. Oncogene, 27, 7183.


